Seattle Genetics Inc. (Nasdaq: SGEN)

https://www.seagen.com

Seattle Genetics is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer. The company's lead program, ADCETRIS (brentuximab vedotin), received accelerated approval from the U.S. Food and Drug Administration in August 2011 and approval with conditions from Health Canada in February 2013 for two indications. In addition, under a collaboration with Millennium: The Takeda Oncology Company, ADCETRIS received conditional approval from the European Commission in October 2012. Seattle Genetics also has four other clinical-stage ADC programs: SGN-75, ASG-5ME, ASG-22ME and SGN-CD19A. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Celldex, Daiichi Sankyo, Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as ADC co-development agreements with Agensys and Genmab. *

	Start	1997-01-01 established
	End	2020-10-08 renamed
	Group	Seagen (Group)
	Today	Seagen Inc. (Nasdaq: SGEN)
	Successor	Seagen Inc. (Nasdaq: SGEN)
	Industry	BIOTECH

	Region	Bothell, WA
	Country	United States (USA)
	Street	21717 30th Drive S.E.
	City	98021 Bothell, WA
	Tel	+1-425-527-4000
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	22,420,000 (revenue, consolidated (2007) 2007-12-31)
	Profit	-48,932,000 (2007-12-31)
	Cash	111,361,000 (2007-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10